ZA200406553B - Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazoloÄ1,5-bÜpyridazine in nanoparticulate form. - Google Patents
Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazoloÄ1,5-bÜpyridazine in nanoparticulate form. Download PDFInfo
- Publication number
- ZA200406553B ZA200406553B ZA200406553A ZA200406553A ZA200406553B ZA 200406553 B ZA200406553 B ZA 200406553B ZA 200406553 A ZA200406553 A ZA 200406553A ZA 200406553 A ZA200406553 A ZA 200406553A ZA 200406553 B ZA200406553 B ZA 200406553B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- pharmaceutical composition
- compound
- present
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 238000001238 wet grinding Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 2
- 239000011324 bead Substances 0.000 description 15
- 239000012736 aqueous medium Substances 0.000 description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 10
- 238000003801 milling Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000001694 spray drying Methods 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 7
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 6
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 6
- NXMZBNYLCVTRGB-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl)pyrazolo[1,5-b]pyridazine Chemical compound C1=CC(OCC)=CC=C1C1=NN(N=CC=C2)C2=C1C1=CC=C(S(C)(=O)=O)C=C1 NXMZBNYLCVTRGB-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- -1 4-METHANESULFONYL-PHENYL Chemical class 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229910001928 zirconium oxide Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000004610 Internal Lubricant Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0206200.8A GB0206200D0 (en) | 2002-03-15 | 2002-03-15 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200406553B true ZA200406553B (en) | 2005-09-22 |
Family
ID=9933079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200406553A ZA200406553B (en) | 2002-03-15 | 2004-08-17 | Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazoloÄ1,5-bÜpyridazine in nanoparticulate form. |
Country Status (21)
Country | Link |
---|---|
US (1) | US20050153967A1 (ko) |
EP (1) | EP1485098B1 (ko) |
JP (1) | JP2005520824A (ko) |
KR (1) | KR20040091133A (ko) |
CN (1) | CN1642549A (ko) |
AT (1) | ATE350038T1 (ko) |
AU (1) | AU2003208709A1 (ko) |
BR (1) | BR0307427A (ko) |
CA (1) | CA2478758A1 (ko) |
DE (1) | DE60310896T2 (ko) |
EA (1) | EA007201B1 (ko) |
EC (1) | ECSP045295A (ko) |
ES (1) | ES2277634T3 (ko) |
GB (2) | GB0206200D0 (ko) |
IS (1) | IS7378A (ko) |
MX (1) | MXPA04009008A (ko) |
NO (1) | NO20043889L (ko) |
NZ (1) | NZ534179A (ko) |
PL (1) | PL372932A1 (ko) |
WO (1) | WO2003077920A1 (ko) |
ZA (1) | ZA200406553B (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60305053T2 (de) | 2002-08-19 | 2006-08-31 | Glaxo Group Ltd., Greenford | Pyrimidinderivate als selektive cox-2-inhibitoren |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP1369421B1 (en) * | 1997-09-05 | 2004-11-03 | Glaxo Group Limited | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives |
BR0008060A (pt) * | 1999-12-08 | 2002-02-05 | Pharmacia Corp | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica |
WO2002000196A2 (en) * | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
-
2002
- 2002-03-15 GB GBGB0206200.8A patent/GB0206200D0/en not_active Ceased
-
2003
- 2003-03-13 CN CNA038061058A patent/CN1642549A/zh active Pending
- 2003-03-13 AT AT03706615T patent/ATE350038T1/de not_active IP Right Cessation
- 2003-03-13 EP EP03706615A patent/EP1485098B1/en not_active Expired - Lifetime
- 2003-03-13 PL PL03372932A patent/PL372932A1/xx not_active Application Discontinuation
- 2003-03-13 KR KR10-2004-7014357A patent/KR20040091133A/ko not_active Application Discontinuation
- 2003-03-13 GB GB0419971A patent/GB2402335B/en not_active Expired - Fee Related
- 2003-03-13 ES ES03706615T patent/ES2277634T3/es not_active Expired - Lifetime
- 2003-03-13 MX MXPA04009008A patent/MXPA04009008A/es not_active Application Discontinuation
- 2003-03-13 CA CA002478758A patent/CA2478758A1/en not_active Abandoned
- 2003-03-13 EA EA200400864A patent/EA007201B1/ru not_active IP Right Cessation
- 2003-03-13 JP JP2003575973A patent/JP2005520824A/ja active Pending
- 2003-03-13 BR BR0307427-7A patent/BR0307427A/pt not_active IP Right Cessation
- 2003-03-13 DE DE60310896T patent/DE60310896T2/de not_active Expired - Fee Related
- 2003-03-13 AU AU2003208709A patent/AU2003208709A1/en not_active Abandoned
- 2003-03-13 NZ NZ534179A patent/NZ534179A/en unknown
- 2003-03-13 WO PCT/EP2003/002698 patent/WO2003077920A1/en active IP Right Grant
- 2003-03-13 US US10/506,934 patent/US20050153967A1/en not_active Abandoned
-
2004
- 2004-07-29 IS IS7378A patent/IS7378A/is unknown
- 2004-08-17 ZA ZA200406553A patent/ZA200406553B/en unknown
- 2004-09-14 EC EC2004005295A patent/ECSP045295A/es unknown
- 2004-09-16 NO NO20043889A patent/NO20043889L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE60310896T2 (de) | 2007-05-10 |
JP2005520824A (ja) | 2005-07-14 |
EP1485098A1 (en) | 2004-12-15 |
BR0307427A (pt) | 2004-12-28 |
IS7378A (is) | 2004-07-29 |
KR20040091133A (ko) | 2004-10-27 |
WO2003077920A1 (en) | 2003-09-25 |
EA007201B1 (ru) | 2006-08-25 |
DE60310896D1 (de) | 2007-02-15 |
US20050153967A1 (en) | 2005-07-14 |
ES2277634T3 (es) | 2007-07-16 |
MXPA04009008A (es) | 2004-12-07 |
GB2402335B (en) | 2005-10-12 |
ATE350038T1 (de) | 2007-01-15 |
CA2478758A1 (en) | 2003-09-25 |
CN1642549A (zh) | 2005-07-20 |
PL372932A1 (en) | 2005-08-08 |
EA200400864A1 (ru) | 2005-02-24 |
AU2003208709A1 (en) | 2003-09-29 |
EP1485098B1 (en) | 2007-01-03 |
GB2402335A (en) | 2004-12-08 |
NZ534179A (en) | 2006-07-28 |
GB0419971D0 (en) | 2004-10-13 |
NO20043889L (no) | 2004-09-16 |
ECSP045295A (es) | 2004-10-26 |
GB0206200D0 (en) | 2002-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6033945B2 (ja) | アピキサバン製剤 | |
US20180296514A1 (en) | Novel formulation of diclofenac | |
RU2485947C2 (ru) | Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью | |
AU757547B2 (en) | Novel compositions of eprosartan | |
AU2022238423A1 (en) | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative | |
JP2010536798A (ja) | 難溶性薬物の生体利用率を制御するための方法及び組成物 | |
AU2009337766B2 (en) | Pharmaceutical formulation of nanonised fenofibrate | |
CN113795243A (zh) | 含有对乙酰氨基酚和布洛芬的药物组合物 | |
US20030022928A1 (en) | Novel compositions of eprosartan | |
EP1485098B1 (en) | Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo¬1,5-b|pyridazine in nanoparticulate form | |
JPWO2002060448A1 (ja) | 医薬組成物 | |
US20140255480A1 (en) | Pharmaceutical formulation of nanonized fenofibrate | |
MXPA00008888A (en) | Novel compositions of eprosartan |